RxDoctor Payments DataLook up a doctor →

Steve Lee, MD

Interventional Pain Medicine · Slidell, LANPI 1699971465

Payments from drug & device makers

$60,903in general payments, 2019–2025

Across 899 payments — averaging $67.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Interventional Pain Technologies Inc.$15K
  • Saluda Medical Americas, Inc.$6K
  • Nevro Corp.$6K
  • Boston Scientific$5K
  • Spinal Simplicity, LLC$4K
  • Surgentec$3K
  • plus $22K from 54 others

What the payments were for

  • Consulting fees$14,20025%
  • Speaking & faculty fees$1,0002%
  • Travel & lodging$8,49215%
  • Food & beverage$21,23938%
  • Education$11,57220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Interventional Pain Technologies Inc.10$14,500
Saluda Medical Americas, Inc.30$6,430
Nevro Corp.140$5,567
Boston Scientific31$5,372
Spinal Simplicity, LLC21$3,768
Surgentec3$3,229
Camber Spine Technologies LLC2$3,000
Abbott99$2,205
Medtronic(2 entities)40$1,854
Collegium Pharmaceutical, Inc.90$1,353
Biodelivery Sciences International, Inc.23$1,250
Genesys Orthopedics Systems, L.L.C.6$1,134
Relievant Medsystems, Inc.13$1,029
Stryker8$942
Titan Pharmaceuticals, Inc.4$780
Amgen(2 entities)53$672
Nalu Medical, Inc.13$629
Forte Bio-pharma LLC17$477
Globus Medical18$463
Pacira Pharmaceuticals Incorporated6$422
MML US, Inc.6$355
Virtus Pharmaceuticals LLC25$345
Arbor Pharmaceuticals, Inc.22$339
IBSA Pharma Inc.18$337
AbbVie(2 entities)17$297
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$268
Stratus Medical, LLC3$214
Biohaven Pharmaceutical Holding Company Ltd.10$206
Sentynl Therapeutics, Inc.15$199
Vertiflex, Inc.9$181
Almatica Pharma LLC9$155
Biotronik NRO, Inc.5$143
SPR Therapeutics, Inc6$142
Painteq LLC2$140
Tersera Therapeutics LLC8$137
Indivior Inc.8$137
Nutech Spine, Inc.1$130
Stimwave Technologies Incorporated2$129
Zyla Life Sciences, Inc.14$126
Sanofi1$125
GRT US Holding, Inc.6$124
Curonix LLC1$109
MDD US Operations, LLC3$106
Pfizer7$105
Redhill Biopharma Inc.6$93
Bioventus LLC3$91
Vertex2$91
Azurity Pharmaceuticals, Inc.4$87
Scilex Pharmaceuticals Inc.5$83
Daiichi Sankyo Inc.5$82
Supernus Pharmaceuticals, Inc.3$75
Biohaven Pharmaceuticals, Inc.4$68
Boehringer Ingelheim1$60
Alkermes, Inc.3$52
Orexo US, Inc.3$49
Vertos Medical, Inc.2$35
Pacira Therapeutics, Inc.2$26
Merz North America, Inc.1$26
Upsher-smith Laboratories LLC1$25
Fidia Pharma USA Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,903 in reported general payments places this provider in the 90th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$107,699
Medicare patients
240
Services billed
1,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl203$175,123
Xtampza ErOxycodone Myristate288$133,384
Levorphanol Tartrate37$97,364
Buprenorphine173$56,813
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen886$29,198
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl155$21,269
OxycontinOxycodone Hcl40$20,289
Nucynta ErTapentadol Hcl14$15,433
HorizantGabapentin Enacarbil21$14,153
GraliseGabapentin16$13,161
ZubsolvBuprenorphine Hcl/Naloxone Hcl23$12,815
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen908$12,499
NucyntaTapentadol Hcl15$11,425
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$10,253
Morphine Sulfate ErMorphine Sulfate284$6,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta$1,353$335,364520 claims
Virtus Pharmaceuticals LLCLevorphanol Tartrate$345$97,36437 claims
Arbor Pharmaceuticals, Inc.Horizant$339$14,15321 claims
Almatica Pharma LLCGralise$155$13,16116 claims
Orexo US, Inc.Zubsolv$49$12,81523 claims
Indivior Inc.Suboxone$137$10,25320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 interventional pain medicine providers in Louisiana.

Other interventional pain medicine in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →